10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||||||
| ||||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
MERCK & CO., INC. | |||
Ticker: MRK Fiscal Year: 2012 | |||
Consolidated Statement of Income | |||
Period Ending Dec 31, 2012 10-K (Filed: Feb 28, 2013) | |||
| (In Millions, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2012 | Dec 31, 2011 | Dec 31, 2010 | |
| Sales | $ 47,267 | 48,047 | 45,987 |
| Costs, Expenses and Other | |||
| Materials and production | 16,446 | 16,871 | 18,396 |
| Marketing and administrative | 12,776 | 13,733 | 13,125 |
| Research and development | 8,168 | 8,467 | 11,111 |
| Restructuring costs | 664 | 1,306 | 985 |
| Equity income from affiliates | (642) | (610) | (587) |
| Other (income) expense, net | 1,116 | 946 | 1,304 |
| Total Costs, Expenses and Other | 38,528 | 40,713 | 44,334 |
| Income Before Taxes | 8,739 | 7,334 | 1,653 |
| Taxes on Income | 2,440 | 942 | 671 |
| Net Income | 6,299 | 6,392 | 982 |
| Less: Net Income Attributable to Noncontrolling Interests | 131 | 120 | 121 |
| Net Income Attributable to Merck & Co., Inc. | 6,168 | 6,272 | 861 |
| Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders | 2.03 | 2.04 | 0.28 |
| Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders | 2.00 | 2.02 | 0.28 |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
MERCK & CO., INC. | |||
Ticker: MRK Fiscal Year: 2012 | |||
Consolidated Statement of Comprehensive Income | |||
Period Ending Dec 31, 2012 10-K (Filed: Feb 28, 2013) | |||
| (In Millions, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2012 | Dec 31, 2011 | Dec 31, 2010 | |
| Net Income Attributable to Merck & Co., Inc. | $ 6,168 | 6,272 | 861 |
| Other Comprehensive (Loss) Income Net of Taxes: | |||
| Net unrealized (loss) gain on derivatives, net of reclassifications | (101) | (37) | 83 |
| Net unrealized gain (loss) on investments, net of reclassifications | 52 | (10) | (2) |
| Benefit plan net (loss) gain and prior service (credit) cost, net of amortization | (1,321) | (303) | 426 |
| Cumulative translation adjustment | (180) | 434 | (956) |
| Total Other Comprehensive (Loss) Income Net of Taxes | (1,550) | 84 | (449) |
| Comprehensive Income Attributable to Merck & Co., Inc. | 4,618 | 6,356 | 412 |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
MERCK & CO., INC. | |||
Ticker: MRK Fiscal Year: 2012 | |||
Consolidated Statement of Cash Flows | |||
Period Ending Dec 31, 2012 10-K (Filed: Feb 28, 2013) | |||
| (In Millions, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2012 | Dec 31, 2011 | Dec 31, 2010 | |
| Cash Flows from Operating Activities | |||
| Net income | $ 6,299 | 6,392 | 982 |
| Adjustments to reconcile net income to net cash provided by operating activities: | |||
| Depreciation and amortization | 6,978 | 7,427 | 7,381 |
| Intangible asset impairment charges | 200 | 705 | 2,441 |
| Gain on disposition of interest in equity method investment | (136) | ||
| Gain on AstraZeneca LP asset option exercise | (443) | ||
| Equity income from affiliates | (642) | (610) | (587) |
| Dividends and distributions from equity affiliates | 291 | 216 | 324 |
| Deferred income taxes | 669 | (1,537) | (1,092) |
| Share-based compensation | 335 | 369 | 509 |
| Other | 28 | 323 | 377 |
| Net changes in assets and liabilities: | |||
| Accounts receivable | 349 | (1,168) | (1,089) |
| Inventories | (482) | (678) | 1,990 |
| Trade accounts payable | (302) | 182 | 124 |
| Accrued and other current liabilities | (717) | 1,444 | 35 |
| Income taxes payable | (34) | (277) | 128 |
| Noncurrent liabilities | (1,747) | (7) | (98) |
| Other | (1,203) | (262) | (160) |
| Net Cash Provided by Operating Activities | 10,022 | 12,383 | 10,822 |
| Cash Flows from Investing Activities | |||
| Capital expenditures | (1,954) | (1,723) | (1,678) |
| Purchases of securities and other investments | (12,841) | (7,325) | (7,197) |
| Proceeds from sales of securities and other investments | 7,783 | 6,149 | 4,561 |
| Proceeds from sale of interest in equity method investment | 175 | ||
| Acquisitions of businesses, net of cash acquired | (373) | (256) | |
| Dispositions of businesses, net of cash divested | 323 | ||
| Proceeds from AstraZeneca LP asset option exercise | 647 | ||
| Decrease in restricted assets | 34 | 276 | |
| Other | 173 | (116) | 150 |
| Net Cash Used in Investing Activities | (6,805) | (2,890) | (3,497) |
| Cash Flows from Financing Activities | |||
| Net change in short-term borrowings | 624 | 1,076 | 90 |
| Payments on debt | (22) | (1,547) | (1,341) |
| Proceeds from issuance of debt | 2,562 | 1,999 | |
| Purchases of treasury stock | (2,591) | (1,921) | (1,593) |
| Dividends paid to stockholders | (5,116) | (4,691) | (4,734) |
| Other dividends paid | (120) | (120) | (119) |
| Proceeds from exercise of stock options | 1,310 | 321 | 363 |
| Other | 86 | (22) | (106) |
| Net Cash Used in Financing Activities | (3,267) | (6,904) | (5,441) |
| Effect of Exchange Rate Changes on Cash and Cash Equivalents | (30) | 42 | (295) |
| Net (Decrease) Increase in Cash and Cash Equivalents | (80) | 2,631 | 1,589 |
| Cash and Cash Equivalents at Beginning of Year | 13,531 | 10,900 | |
| Cash and Cash Equivalents at End of Year | 13,451 | 13,531 | 10,900 |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||
MERCK & CO., INC. | ||
Ticker: MRK Fiscal Year: 2012 | ||
Consolidated Balance Sheet | ||
Period Ending Dec 31, 2012 10-K (Filed: Feb 28, 2013) | ||
| (In Millions, except shares in actual) | ||
| As of | As of | |
| Dec 31, 2012 | Dec 31, 2011 | |
| Assets | ||
| Current Assets | ||
| Cash and cash equivalents | $ 13,451 | 13,531 |
| Short-term investments | 2,690 | 1,441 |
| Accounts receivable (net of allowance for doubtful accounts of $163 in 2012 and $131 in 2011) | 7,672 | 8,261 |
| Inventories (excludes inventories of $1,606 in 2012 and $1,379 in 2011 classified in Other assets - see Note 7) | 6,535 | 6,254 |
| Deferred income taxes and other current assets | 4,509 | 3,694 |
| Total current assets | 34,857 | 33,181 |
| Investments | 7,305 | 3,458 |
| Property, Plant and Equipment (at cost) | ||
| Land | 591 | 623 |
| Buildings | 13,196 | 12,733 |
| Machinery, equipment and office furnishings | 17,188 | 16,919 |
| Construction in progress | 2,440 | 2,198 |
| Property, Plant and Equipment, Gross | 33,415 | 32,473 |
| Less: accumulated depreciation | 17,385 | 16,176 |
| Property, Plant and Equipment, Net, Total | 16,030 | 16,297 |
| Goodwill | 12,134 | 12,155 |
| Other Intangibles, Net | 29,083 | 34,302 |
| Other Assets | 6,723 | 5,735 |
| Total Assets | 106,132 | 105,128 |
| Liabilities and Equity | ||
| Current Liabilities | ||
| Loans payable and current portion of long-term debt | 4,315 | 1,990 |
| Trade accounts payable | 1,753 | 2,023 |
| Accrued and other current liabilities | 9,737 | 10,170 |
| Income taxes payable | 1,200 | 781 |
| Dividends payable | 1,343 | 1,281 |
| Total current liabilities | 18,348 | 16,245 |
| Long-Term Debt | 16,254 | 15,525 |
| Deferred Income Taxes and Noncurrent Liabilities | 16,067 | 16,415 |
| Merck & Co., Inc. Stockholders' Equity | ||
| Common stock, $0.50 par value, Authorized - 6,500,000,000 shares, Issued - 3,577,103,522 shares in 2012 and 2011 | 1,788 | 1,788 |
| Other paid-in capital | 40,646 | 40,663 |
| Retained earnings | 39,985 | 38,990 |
| Accumulated other comprehensive loss | (4,682) | (3,132) |
| Stockholders' equity before deduction for treasury stock | 77,737 | 78,309 |
| Less treasury stock, at cost: 550,468,221 shares in 2012; 536,109,713 shares in 2011 | 24,717 | 23,792 |
| Total Merck & Co., Inc. stockholders' equity | 53,020 | 54,517 |
| Noncontrolling Interests | 2,443 | 2,426 |
| Total equity | 55,463 | 56,943 |
| Liabilities and Equity | 106,132 | 105,128 |
| External Links | |
| MERCK & CO., INC. (MRK) Fiscal Year 2012 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |